Shares of Vir Biotechnology, Inc. (VIR) gained over 16% on Wednesday morning after the company reported that Tobevibart Monotherapy and combination therapy with Elebsiran achieved high virologic response and normalization in people living with the Hepatitis Delta virus.
VIR is currently trading at $12.37, up $1.79 or 16.88%, on the Nasdaq. The stock opened its trading at $12.18 after closing Tuesday at $10.58. The stock has traded between $7.61 and $27.48 in the past 52-week period.
Vir Biotechnology in a new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta.
Preliminary data from the Phase 2 trial show treatment with tobevibart alone or in combination with elebsiran was generally well tolerated and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.